Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1926 1
1976 1
1984 1
1987 1
1991 1
1995 1
1997 2
1998 1
1999 1
2000 1
2001 2
2002 4
2003 2
2004 1
2005 4
2006 4
2007 4
2008 7
2009 5
2010 12
2011 13
2012 10
2013 12
2014 23
2015 19
2016 26
2017 22
2018 33
2019 32
2020 38
2021 38
2022 49
2023 49
2024 14

Text availability

Article attribute

Article type

Publication date

Search Results

381 results

Results by year

Filters applied: . Clear all
The following terms were ignored: %, %, %
The following terms were not found in PubMed: 20Grace, 20Sparrow
Page 1
Clinical Pharmacokinetics and Pharmacodynamics of Cefepime.
Pais GM, Chang J, Barreto EF, Stitt G, Downes KJ, Alshaer MH, Lesnicki E, Panchal V, Bruzzone M, Bumanglag AV, Burke SN, Scheetz MH. Pais GM, et al. Clin Pharmacokinet. 2022 Jul;61(7):929-953. doi: 10.1007/s40262-022-01137-y. Epub 2022 Jun 29. Clin Pharmacokinet. 2022. PMID: 35764774 Free PMC article. Review.
Cefepime is widely distributed in biological fluids and tissues with an average volume of distribution of ~ 0.2 L/kg in healthy adults with normal renal function. Protein binding is relatively low (20%), and elimination is mainly renal. About 85% of the dose is excreted un …
Cefepime is widely distributed in biological fluids and tissues with an average volume of distribution of ~ 0.2 L/kg in healthy adults with …
Antimicrobial Prophylaxis for Adult Patients With Cancer-Related Immunosuppression: ASCO and IDSA Clinical Practice Guideline Update.
Taplitz RA, Kennedy EB, Bow EJ, Crews J, Gleason C, Hawley DK, Langston AA, Nastoupil LJ, Rajotte M, Rolston KV, Strasfeld L, Flowers CR. Taplitz RA, et al. J Clin Oncol. 2018 Oct 20;36(30):3043-3054. doi: 10.1200/JCO.18.00374. Epub 2018 Sep 4. J Clin Oncol. 2018. PMID: 30179565
Pneumocystis jirovecii prophylaxis is recommended for patients receiving chemotherapy regimens that are associated with a > 3.5% risk for pneumonia as a result of this organism (eg, those with 20 mg prednisone equivalents daily for 1 month or on the basis of purine anal …
Pneumocystis jirovecii prophylaxis is recommended for patients receiving chemotherapy regimens that are associated with a > 3.5% risk for …
Early intensive behavioral intervention (EIBI) for young children with autism spectrum disorders (ASD).
Reichow B, Hume K, Barton EE, Boyd BA. Reichow B, et al. Cochrane Database Syst Rev. 2018 May 9;5(5):CD009260. doi: 10.1002/14651858.CD009260.pub3. Cochrane Database Syst Rev. 2018. PMID: 29742275 Free PMC article. Review.
Early intensive behavioral intervention (EIBI) is a treatment based on the principles of applied behavior analysis. Delivered for multiple years at an intensity of 20 to 40 hours per week, it is one of the more well-established treatments for ASD. ...
Early intensive behavioral intervention (EIBI) is a treatment based on the principles of applied behavior analysis. Delivered for multiple y …
Safety and efficacy of valbenazine for the treatment of chorea associated with Huntington's disease (KINECT-HD): a phase 3, randomised, double-blind, placebo-controlled trial.
Furr Stimming E, Claassen DO, Kayson E, Goldstein J, Mehanna R, Zhang H, Liang GS, Haubenberger D; Huntington Study Group KINECT-HD Collaborators. Furr Stimming E, et al. Lancet Neurol. 2023 Jun;22(6):494-504. doi: 10.1016/S1474-4422(23)00127-8. Lancet Neurol. 2023. PMID: 37210099 Clinical Trial.
Angiotensin II Infusion for Shock: A Multicenter Study of Postmarketing Use.
Wieruszewski PM, Wittwer ED, Kashani KB, Brown DR, Butler SO, Clark AM, Cooper CJ, Davison DL, Gajic O, Gunnerson KJ, Tendler R, Mara KC, Barreto EF. Wieruszewski PM, et al. Chest. 2021 Feb;159(2):596-605. doi: 10.1016/j.chest.2020.08.2074. Epub 2020 Aug 31. Chest. 2021. PMID: 32882250 Free PMC article.
Responders showed a greater increase in MAP (+10.3 mm Hg vs +1.6 mm Hg, P < .001) and reduction in vasopressor dosage (-0.20 mug/kg/min vs +0.04 mug/kg/min; P < .001) compared with nonresponders at 3 h. ...

Responders showed a greater increase in MAP (+10.3 mm Hg vs +1.6 mm Hg, P < .001) and reduction in vasopressor dosage (-0.20 mug/k

…
An Update on the Treatment of Chorea.
Feinstein E, Walker R. Feinstein E, et al. Curr Treat Options Neurol. 2018 Sep 25;20(10):44. doi: 10.1007/s11940-018-0529-y. Curr Treat Options Neurol. 2018. PMID: 30255459 Review.
Matching-adjusted indirect comparison of isatuximab plus carfilzomib and dexamethasone with daratumumab plus lenalidomide and dexamethasone in relapsed multiple myeloma.
Richter J, Lin PL, Garcia-Horton V, Guyot P, Singh E, Zhou ZY, Sievert M, Taiji R. Richter J, et al. Cancer Med. 2023 Apr;12(7):8005-8017. doi: 10.1002/cam4.5584. Epub 2023 Feb 1. Cancer Med. 2023. PMID: 36726287 Free PMC article.
Isa-Kd showed significantly better PFS (HR [95% CI]: 0.46 [0.24-0.86]; p = 0.0155), statistically non-significant improvement favoring Isa-Kd in OS (0.47 [0.20-1.09]; 0.0798), and VGPR (OR [95% CI]: 1.53 [0.89-2.64]; p = 0.1252) than Dara-Rd. ...
Isa-Kd showed significantly better PFS (HR [95% CI]: 0.46 [0.24-0.86]; p = 0.0155), statistically non-significant improvement favoring Isa-K …
Concepts to Bolster Biorisk Management.
Dettmann RA, Ritterson R, Lauer E, Casagrande R. Dettmann RA, et al. Health Secur. 2022 Sep-Oct;20(5):376-386. doi: 10.1089/hs.2022.0074. Epub 2022 Aug 23. Health Secur. 2022. PMID: 35997589
Evaluation of Hepatitis C Screening and Treatment Among Psychiatry Inpatients.
Mandel E, Biondi MJ, Mendlowitz A, Maheandiran M, Hollingdrake E, Vanderhoff A, Wolfson-Stofko B, Capraru C, Feld JJ, Logan R. Mandel E, et al. J Clin Psychiatry. 2023 Jul 31;84(5):22m14623. doi: 10.4088/JCP.22m14623. J Clin Psychiatry. 2023. PMID: 37530609 Review.
Results: Of 1,031 patients, 73% (n = 753) were male, mean age was 44 years (range: 20-92), and mean length of stay was 7.1 months (range: 0 days-24 years). ...
Results: Of 1,031 patients, 73% (n = 753) were male, mean age was 44 years (range: 20-92), and mean length of stay was 7.1 months (ra …
381 results